Results 21 to 30 of about 80,266 (330)

Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2

eLife, 2023
The Tec-family kinase Btk contains a lipid-binding Pleckstrin homology and Tec homology (PH-TH) module connected by a proline-rich linker to a ‘Src module’, an SH3-SH2-kinase unit also found in Src-family kinases and Abl. We showed previously that Btk is
Laura M Nocka, Timothy J Eisen, Anthony T Iavarone, Jay T Groves, John Kuriyan   +4 more
doaj   +1 more source

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Cancers, 2023
Simple Summary Chronic lymphocytic leukemia (CLL) treatment scenario is rapidly evolving. As a consequence of longer observation, despite remarkable clinical results, treatment with ibrutinib is associated with long-term toxicities and resistance.
A. Frustaci, M. Deodato, G. Zamprogna, R. Cairoli, M. Montillo, A. Tedeschi   +5 more
semanticscholar   +1 more source

Stretched exponential relaxation in the mode-coupling theory for the Kardar-Parisi-Zhang equation [PDF]

, 2000
We study the mode-coupling theory for the Kardar-Parisi-Zhang equation in the strong-coupling regime, focusing on the long time properties. By a saddle point analysis of the mode-coupling equations, we derive exact results for the correlation function in
Cesnik C. E. S., Cesnik C.E.S., Lockyer A. J., Mukhopadhyay V., Peters D. A., Su W., Su W., Tilmann C.P., VanShoor M.C., Wakayama S.   +9 more
core   +5 more sources

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

eLife, 2020
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph, Neha Amatya, D Bruce Fulton, John R Engen, Thomas E Wales, Amy Andreotti   +5 more
doaj   +1 more source

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Blood Advances, 2022
The covalent Bruton’s tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations ...
P. Blombery, E. Thompson, T. Lew, I. Tiong, R. Bennett, C. Cheah, K. Lewis, S. Handunnetti, C. Tang, A. Roberts, J. Seymour, C. Tam   +11 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae

Journal of Innate Immunity, 2022
Humans with dysfunctional Bruton’s tyrosine kinase (Btk) are highly susceptible to bacterial infections. Compelling evidence indicates that Btk is essential for B cell-mediated immunity, whereas its role in myeloid cell-mediated immunity against ...
Zhe Liu, Alexander P.N.A. De Porto, Regina De Beer, Joris J.T.H. Roelofs, Onno J. De Boer, Sandrine Florquin, Cornelis Van’t Veer, Rudi W. Hendriks, Tom Van der Poll, Alex F. De Vos   +9 more
doaj   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

Genes, 2023
Bruton’s tyrosine kinase (BTK) plays a key role in the B-cell receptor (BCR) signaling pathway and confers anti-apoptotic and proliferative properties to malignant B-cells in chronic lymphocytic leukemia (CLL). Small molecule BTK inhibitors were designed
Alexandra Chirino, S. Montoya, Anita Safronenka, Justin Taylor   +3 more
semanticscholar   +1 more source

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

Journal of Hematology & Oncology, 2021
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li, Yi Miao   +4 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source